Evidence map›Paper›PMID 35201488›Full record

ReviewDiscover oncology2021

Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer.

Carlo Ganini, Ivano Amelio, Riccardo Bertolo, Eleonora Candi, Angela Cappello, Chiara Cipriani, Alessandro Mauriello, Carla Marani, Gerry Melino, Manuela Montanaro and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Discover oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 3 countries.

Carlo GaniniDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy. carlo.ganini@students.uniroma2.eu.ORCID http://orcid.org/0000-0002-5839-3965
Ivano AmelioDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-0739-325X
Riccardo BertoloDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-0260-4601
Eleonora CandiDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-8332-4825
Angela CappelloDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-0893-445X
Chiara CiprianiDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-7085-4966
Alessandro MaurielloDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0002-7351-5676
Carla MaraniDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-1199-0372
Gerry MelinoDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-9428-5972
Manuela MontanaroDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-8441-3731
Maria Emanuela NataleDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.
Giuseppe TisoneDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-8860-5909
Yufang ShiDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-8964-319X
Ying WangCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200031, China.ORCID http://orcid.org/0000-0002-2571-9367
Pierluigi BoveDepartment of Experimental Medicine, Torvergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, a Montpellier 1, 00133, Rome, Italy. pierluigi.bove@uniroma2.it.ORCID http://orcid.org/0000-0002-4788-2982
University of Rome Tor Vergata · ITShanghai Institute of Nutrition and Health · CN

Funding

Associazione Italiana per la Ricerca sul Cancro AIRC Start-Up ID 23219Associazione Italiana per la Ricerca sul Cancro IG#20473Associazione Italiana per la Ricerca sul Cancro IG#22206Ministero della Salute #PGR00961
6 · The paper itself

Abstract

Serine and one-carbon unit metabolisms are essential biochemical pathways implicated in fundamental cellular functions such as proliferation, biosynthesis of important anabolic precursors and in general for the availability of methyl groups. These two distinct but interacting pathways are now becoming crucial in cancer, the de novo cytosolic serine pathway and the mitochondrial one-carbon metabolism. Apart from their role in physiological conditions, such as epithelial proliferation, the serine metabolism alterations are associated to several highly neoplastic proliferative pathologies. Accordingly, prostate cancer shows a deep rearrangement of its metabolism, driven by the dependency from the androgenic stimulus. Several new experimental evidence describes the role of a few of the enzymes involved in the serine metabolism in prostate cancer pathogenesis. The aim of this study is to analyze gene and protein expression data publicly available from large cancer specimens dataset, in order to further dissect the potential role of the abovementioned metabolism in the complex reshaping of the anabolic environment in this kind of neoplasm. The data suggest a potential role as biomarkers as well as in cancer therapy for the genes (and enzymes) belonging to the one-carbon metabolism in the context of prostatic cancer.

Indexed as

One-carbon metabolismProstate cancer metabolismSerine

Identifiers

PMID35201488
PMCPMC8777499
OpenAlexW3208600804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.